Our findings showed a novel mechanism, underlying the antimetastatic activity of parecoxib in colorectal cancer by inhibiting p-Akt, p-ERK, p-GSK3β, MACC1, and cMet to induce the inhibition of epithelial–mesenchymal transition (EMT) and β-catenin [24]. Here, AKT1 is linked to colorectal cancer.